

AD_____

Award Number: W81XWH-12-1-0428

TITLE: Role of Grainyhead in Kidney Cancer

PRINCIPAL INVESTIGATOR: Steven Frisch

CONTRACTING ORGANIZATION: West Virginia University
Morgantown, WV 26506-9142

REPORT DATE: October 2013

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE				Form Approved OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.					
1. REPORT DATE October 2013		2. REPORT TYPE Annual		3. DATES COVERED 30 September 2012-29 September 2013	
4. TITLE AND SUBTITLE Role of Grainyhead in Kidney Cancer				5a. CONTRACT NUMBER	
				5b. GRANT NUMBER W81XWH-12-1-0428	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Steven Frisch E-Mail: sfrisch@hsc.wvu.edu				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) West Virginia University Dept. Of Biochemistry and Molecular Pharmacology PO Box 9142 Morgantown, WV 26506-9142				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT The cell of origin in clear cell renal cell carcinoma (ccRCC) is ambiguous. Previously, we had found through microarray "data mining", that Grainyhead-like-2 (GRHL2) was expressed at much lower levels in ccRCC compared with normal kidney. In light of the relatively high overall expression of GRHL2 in the kidney, compared with other organs, we interpreted this result to mean that GRHL2 was down-regulated during oncogenic transformation. Our recent data, however, indicate that the much more likely interpretation is that ccRCC arises from GRHL2-negative cells of origin. These data include: a. low or undetectable expression levels of GRHL2 in either normal proximal or distal tubule-derived cell lines; b. low immunohistochemical signal for GRHL2 in normal proximal or distal tubules of human kidney samples; c. very high signal for GRHL2 in collecting duct and ureter. These results are highly significant because they show that ccRCC arises uniquely from GRHL2-negative but not GRHL2-positive ductal epithelial cells, informing a novel understanding of the biology of ccRCC.					
15. SUBJECT TERMS Grainyhead-like-2/kidney/collecting ducts/proximal tubules/distal tubules/clear cell renal carcinoma					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT UU	18. NUMBER OF PAGES 9	19a. NAME OF RESPONSIBLE PERSON USAMRMC
a. REPORT U	b. ABSTRACT U	c. THIS PAGE U			19b. TELEPHONE NUMBER (include area code)

Table of Contents

	<u>Page</u>
1. Introduction	4
2. Keywords	4
3. Overall Project Summary	4
4. Key Research Accomplishments	8
5. Conclusion	8
6. Publications, Abstracts, and Presentations	8
7. Inventions, Patents and Licenses	8
8. Reportable Outcomes	8
9. Other Achievements	8
10. References	9
11. Appendices	N/A

1. INTRODUCTION: The original intent of our project was to test the role of an epithelial master-programming transcription factor called Grainyhead-like-2 (GRHL2) in preventing the Epithelial-to-Mesenchymal Transition that was believed to be a characteristic of clear cell renal carcinoma (ccRCC). We were also planning to test the role of GRHL2 in regulating anoikis in normal and transformed renal cells. New and surprising results were obtained, as described below, that inform a new perspective on this problem.

2. KEYWORDS: **Anoikis, Epithelial-Mesenchymal Transition,** clear cell renal carcinoma, Grainyhead-like-2, Von Hippel-Lindau protein, proximal tubules, distal tubules, collecting ducts/kidney

3. OVERALL PROJECT SUMMARY:

Objective 1. To determine whether GRHL2 is a tumor suppressor for RCC.

In breast cancer, we had published previously that GRHL2 is a suppressor of the oncogenic epithelial-mesenchymal transition (EMT) that is down-regulated specifically in a subclass of breast cancer (“claudin-low”) that is characterized by widespread EMT (1, 2).

With regard to clear cell renal carcinoma (ccRCC), analysis of published microarray data using the GEO database indicated a significantly decreased expression of GRHL2 in ccRCC compared to normal kidney (figure 1). Moreover, abundant literature has characterized ccRCC as an EMT-derived tumor type (e.g., (3, 4)). Combining these two concepts, we hypothesized that: a. the VHL defect in most ccRCC directly or indirectly down-regulates GRHL2 expression; b. the down-regulation of GRHL2, as in breast cancer, is a critical step for tumor cell commitment to EMT and anoikis-resistance.

With this in mind, we obtained a collection of normal and transformed kidney cell lines and examined the expression of GRHL2 as well as the effect of ectopically expressing GRHL2 on normal vs. tumor phenotypes. This panel included: RCC4 (ccRCC) cells and RCC4 plus VHL re-expression (5); 786-0 ccRCC, 786 plus VHL re-expression (6); HKC-8 (normal proximal tubule cells), HK-2 (normal proximal tubule cells), UMRC3 (ccRCC), UMRC3 with re-expressed Soluble Frizzled Receptor-3 (7), mIMCD3 (inner medullary collecting duct epithelial cells, mouse) and MDCK (distal tubule or collecting duct, canine). The results of these studies were as follows:

- A. Initial preliminary data indicated that all these lines expressed GRHL2 to various extents on western blots, using a well-characterized “Atlas Project” GRHL2 antibody.
- B. There were two problems with the identification of this western blot band as GRHL2, however. First, the band in HKC lysates migrated slightly slower than the known GRHL2 band in control (HMLE cell) lysates (figure 2a). Secondly, three different shRNAs directed against GRHL2 produced little or no knockdown of the band in HKC cells (figure 2b), while significantly knocking down the control GRHL2 band in HMLE cells (1, 2).




Figure1. Decreased expression of GRHL2 in ccRCC compared to normal kidney (1)








Figure 2a. Gel mobility of anti-GRHL2 reactive band differs in HMLE vs. HKC cells.

- C. qRT-PCR data indicated lack of significant expression of GRHL2 mRNA in the cell lines listed above, except in the case of MDCK cells and mIMCD-3 cells – notably, both collecting duct-derived cell lines (although MDCK is sometimes cited as a distal tubule cell line).
- D. By contrast, in the two collecting duct-derived cell lines, mIMCD3 and MDCK, GRHL2 was expressed at high levels, co-migrated with HMLE-derived GRHL2 on a western blot and could be knocked down efficiently with GRHL2 shRNA (figure 4a, 4b and data not shown).
- E. Examination of the Atlas database for tissue specific expression using validated antibodies indicated only weak expression in tubules, that was mostly cytoplasmic (note that GRHL2 is a nuclear transcription factor). By contrast, the urinary bladder (UB) which is of the same tissue origin and cell type (urothelial cells) as the collecting ducts, was highly positive for nuclear GRHL2 (figure 5).

In summary, these results indicate that renal cells derived from the metanephric mesenchyme – which include essentially all the cells within mature nephrons—are essentially negative for GRHL2 expression. These are the cells, however, that give rise to ccRCC. By contrast, the cells of the ureteric tree/collecting duct (epithelial cells induced to form these structures by induction of GDNF/Ret signaling of the Wolffian duct during development) are GRHL2 positive and do not give rise to ccRCC. This raises the important question of whether GRHL2 expression is a potent protective factor against RCC, analogous to its tumor suppressor role in breast cancer.



Objective 2. To determine how GRHL2 suppresses EMT, thus preventing RCC.

As explained above, the precursor cells for ccRCC are GRHL2-negative. Plausibly, it is this property that makes them susceptible to the partial EMT accompanying oncogenic transformation. We therefore examined the effects of GRHL2 expression on the responses of renal epithelial cells to TGF- β and HGF. The rationale for this was that both of these factors contribute significantly to ccRCC development, although TGF- β is a potent pro-fibrotic agent in the kidney while HGF suppresses fibrosis (8-10). Our results are summarized as follows:

- A. Constitutive GRHL2 expression (by infection with a GRHL2 retroviral vector) suppressed the HGF- induced collagen gel invasion of 786-0 cells (figure 6).
- B. In MDCK cells, HGF or constitutive GRHL2 expression each suppress the fibrosis/EMT markers, fibronectin and alpha-smooth muscle actin (figure 7). This indicates that pathways downstream of GRHL2 partially overlap with those downstream of HGF, both producing the effect of suppressing fibrotic/mesenchymal gene expression.

Objective 3. To determine how GRHL2 suppresses EMT-mediated anoikis-resistance, thus preventing RCC progression.

The initial phase of this aim was to test the effect of GRHL2 expression on anoikis sensitivity in normal or ccRCC cell lines. To initiate this study, we expressed GRHL2 in the (GRHL2-negative, VHL-negative) ccRCC cell line, 786-0 and assayed this pair of isogenic cell lines, together with the 786-0+VHL cell line. Interestingly, either re-expression of VHL or ectopic GRHL2 expression sensitized 786-0 cells to anoikis (figure 8).




Figure 5. Expression of GRHL2 by IHC in kidney tubules and urinary bladder (data from <http://www.proteinatlas.org/ENSG00000083307/normal>)




Figure 6. Constitutive GRHL2 expression suppressed the HGF- induced collagen gel invasion of 786-0 cells

Additionally, the constitutive expression of GRHL1, which was expressed endogenously in 786-0 cells at low levels (data not show), also sensitized the cells to anoikis (figure 9).




Figure 7. MDCK cells expressing control shRNA empty vector (pGIPZ) or GRHL2 shRNA (384) were treated with HGF for the indicated times, followed by western blotting for the EMT/fibrosis markers fibronectin, alpha-smooth muscle actin or vimentin.




Figure 8. GRHL2 and VHL sensitize 786-0 RCC cells to anoikis. Assayed by Cell Death ELISA (left) or % PI positive (apoptotic) cells (right).




Figure 9. Constitutive expression of GRHL1 sensitizes 786-0 cells to anoikis.

4. KEY RESEARCH ACCOMPLISHMENTS:

- --Discovery that ccRCC cell lines arise from GRHL2-negative cells of origin within the kidney. This informs the novel question of how GRHL2 expression prevents tumor initiation or progression in ccRCC.
- --Discovery that GRHL2 suppresses anoikis in renal carcinoma
- --Discovery that GRHL2 suppresses collagen gel invasion in ccRCC cells
- --Discovery that GRHL2 suppresses fibrotic/mesenchymal gene expression in renal cells

5. CONCLUSION:

Clear cell RCC is thought to arise from proximal and/or distal tubules within the numerous nephrons of the kidney. Our major significant finding of the past year is that these cell types are, surprisingly, negative for GRHL2 expression, despite having other characteristics of epithelial cells. Interestingly, the anatomically close neighbor, collecting ducts, are highly GRHL2 positive and are not thought to give rise to ccRCC (in fact, they only rarely produce tumors). These results suggest that GRHL2 expression is highly protective against ccRCC. This positions GRHL2 as a tumor suppressor in renal carcinoma, analogous to the effect reported earlier in breast cancer. This will be pursued further by the experiments outlined in the grant application.

6. PUBLICATIONS, ABSTRACTS, AND PRESENTATIONS:

- a. List all manuscripts submitted for publication during the period covered by this report resulting from this project.
Nothing to report
- b. List presentations made during the last year (international, national, local societies, military meetings, etc.). Use an asterisk (*) if presentation produced a manuscript.
Nothing to report

7. INVENTIONS, PATENTS AND LICENSES:

Nothing to report

8. REPORTABLE OUTCOMES:

Clear cell RCC is thought to arise from proximal and/or distal tubules within the numerous nephrons of the kidney. Our major significant finding of the past year is that these cell types are, surprisingly, negative for GRHL2 expression, despite having other characteristics of epithelial cells. Interestingly, the anatomically close neighbor, collecting ducts, are highly GRHL2 positive and are not thought to give rise to ccRCC (in fact, they only rarely produce tumors). These results suggest that GRHL2 expression is highly protective against ccRCC. This positions GRHL2 as a tumor suppressor in renal carcinoma, analogous to the effect reported earlier in breast cancer.

9. OTHER ACHIEVEMENTS:

Nothing to report

10. REFERENCES:

1. B. Cieply *et al.*, *Cancer Res* 72, 2440 (May 1).
2. B. Cieply, J. Farris, J. Denvir, H. L. Ford, S. M. Frisch, *Cancer Res* 73, 6299 (Oct 15).
3. A. J. Pantuck, J. An, H. Liu, M. B. Rettig, *Cancer Res* 70, 752 (Jan 15).
4. H. W. Tun *et al.*, *PLoS One* 5, e10696.
5. S. K. Harten *et al.*, *Mol Biol Cell* 20, 1089 (Feb, 2009).
6. S. Koochekpour *et al.*, *Mol Cell Biol* 19, 5902 (Sep, 1999).
7. M. L. Gumz *et al.*, *Clin Cancer Res* 13, 4740 (Aug 15, 2007).
8. A. Giubellino, W. M. Linehan, D. P. Bottaro, *Expert Rev Anticancer Ther* 9, 785 (Jun, 2009).
9. Y. Liu, J. Yang, *Kidney Int* 70, 238 (Jul, 2006).
10. S. L. Kominsky, M. Doucet, K. Brady, K. L. Weber, *J Bone Miner Res* 22, 37 (Jan, 2007).

11. APPENDICES: N/A